Redwire (RDW) said Tuesday that it was awarded a NASA contract to launch four additional pharmaceutical drug investigations at the International Space Station using the company's pharmaceutical in-space laboratory.
Financial terms were not disclosed.
The NASA-funded investigations aim to manufacture protein-based and other molecular seed crystals which could provide insights and data for low-gravity pharmaceutical manufacturing operations aboard the space station and other commercial space stations in low Earth orbit, the company said.
The company said previous investigations suggest that growing crystals in space could yield a more uniform product with fewer imperfections, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。